ION582

Ionis Pharmaceuticals is moving forward with Phase 3 trials for ION582, an antisense therapy designed to unsilence the paternal UBE3A gene in Angelman syndrome patients, after Biogen declined to license the drug.

Ionis Pharmaceuticals is initiating a Phase 3 trial (REVEAL) for ION582, a potential treatment for Angelman Syndrome, following positive Phase 2 results and FDA agreement.

Ionis Pharmaceuticals has finalized the design for a Phase III clinical trial, named REVEAL, to evaluate ION582 as a potential treatment for Angelman syndrome.

Ionis Pharmaceuticals has announced the design for its Phase III REVEAL study of ION582, an investigational treatment for Angelman Syndrome (AS).

Ionis Pharmaceuticals reports positive progress with WAINUA launch and regulatory approvals in the UK and Europe for ATTRv-PN treatment.